Dr. Betty Murray explains how estrogen-based HRT and GLP-1 drugs like semaglutide work together in the brain to control hunger and metabolism. Postmenopausal women using both treatments lose more body fat and have better metabolic stability than those on GLP-1 drugs alone, according to Mayo Clinic data.
The powerful combination of GLP-1s plus hormone replacement therapy for perimenopause and menopause. This is where the magic can really happen. Estrogen and GLP-1s work synergistically in the central nervous system to regulate satiety, regulate energy expenditure, and glucose handling. And retrospective and clinical data, including recent observational data from institutions like Mayo Clinic, demonstrate that postmenopausal women taking both hormone replacement therapy and a GLP-1 receptor agonist like Ozempic or Wegovy, semaglutide, tirzepatide, show a higher loss of body fat mass and maintained better metabolic stability than women taking a GLP-1 alone.
